These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 32409305)

  • 1. The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment.
    Borst L; van der Burg SH; van Hall T
    Clin Cancer Res; 2020 Nov; 26(21):5549-5556. PubMed ID: 32409305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer.
    Salomé B; Sfakianos JP; Ranti D; Daza J; Bieber C; Charap A; Hammer C; Banchereau R; Farkas AM; Ruan DF; Izadmehr S; Geanon D; Kelly G; de Real RM; Lee B; Beaumont KG; Shroff S; Wang YA; Wang YC; Thin TH; Garcia-Barros M; Hegewisch-Solloa E; Mace EM; Wang L; O'Donnell T; Chowell D; Fernandez-Rodriguez R; Skobe M; Taylor N; Kim-Schulze S; Sebra RP; Palmer D; Clancy-Thompson E; Hammond S; Kamphorst AO; Malmberg KJ; Marcenaro E; Romero P; Brody R; Viard M; Yuki Y; Martin M; Carrington M; Mehrazin R; Wiklund P; Mellman I; Mariathasan S; Zhu J; Galsky MD; Bhardwaj N; Horowitz A
    Cancer Cell; 2022 Sep; 40(9):1027-1043.e9. PubMed ID: 36099881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monalizumab: inhibiting the novel immune checkpoint NKG2A.
    van Hall T; André P; Horowitz A; Ruan DF; Borst L; Zerbib R; Narni-Mancinelli E; van der Burg SH; Vivier E
    J Immunother Cancer; 2019 Oct; 7(1):263. PubMed ID: 31623687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.
    van Montfoort N; Borst L; Korrer MJ; Sluijter M; Marijt KA; Santegoets SJ; van Ham VJ; Ehsan I; Charoentong P; André P; Wagtmann N; Welters MJP; Kim YJ; Piersma SJ; van der Burg SH; van Hall T
    Cell; 2018 Dec; 175(7):1744-1755.e15. PubMed ID: 30503208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody.
    Gong Y; Germeraad WTV; Zhang X; Wu N; Li B; Janssen L; He Z; Gijbels MJJ; Wu B; Gijsbers BLMG; Olieslagers TI; Bos GMJ; Zheng L; Klein Wolterink RGJ
    Mol Ther; 2024 Aug; 32(8):2711-2727. PubMed ID: 38943249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Qa-1
    Zhang X; Sabio E; Krishna C; Ma X; Wang J; Jiang H; Havel JJ; Chan TA
    Mol Cancer Res; 2021 Jun; 19(6):1076-1084. PubMed ID: 33674442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E.
    Battin C; Kaufmann G; Leitner J; Tobias J; Wiedermann U; Rölle A; Meyer M; Momburg F; Steinberger P
    Immunology; 2022 Aug; 166(4):507-521. PubMed ID: 35596615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
    Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
    Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
    André P; Denis C; Soulas C; Bourbon-Caillet C; Lopez J; Arnoux T; Bléry M; Bonnafous C; Gauthier L; Morel A; Rossi B; Remark R; Breso V; Bonnet E; Habif G; Guia S; Lalanne AI; Hoffmann C; Lantz O; Fayette J; Boyer-Chammard A; Zerbib R; Dodion P; Ghadially H; Jure-Kunkel M; Morel Y; Herbst R; Narni-Mancinelli E; Cohen RB; Vivier E
    Cell; 2018 Dec; 175(7):1731-1743.e13. PubMed ID: 30503213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutual exclusivity and co-occurrence patterns of immune checkpoints indicate NKG2A relates to anti-PD-1 resistance in gastric cancer.
    Li G; Liu X; Gu C; Ma G; Li S; Ma Z; Xiong Y; Jiang Y; Huang Q; Wu J; Wu Z; Liao W; Wu Q; Shi M
    J Transl Med; 2024 Aug; 22(1):718. PubMed ID: 39097734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity.
    Fisher JG; Graham LV; Blunt MD
    Oncotarget; 2024 Jul; 15():501-503. PubMed ID: 39018202
    [No Abstract]   [Full Text] [Related]  

  • 12. Differential prognostic impact of CD8
    Kwak Y; Koh J; Park Y; Hong YJ; Park KU; Kim HH; Park DJ; Ahn SH; Kim WH; Lee HS
    Br J Cancer; 2020 Apr; 122(9):1399-1408. PubMed ID: 32203213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing Natural Killer and CD8
    Ravindranath MH; Filippone EJ; Devarajan A; Asgharzadeh S
    Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):38-59. PubMed ID: 31009335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice.
    Li F; Wei H; Wei H; Gao Y; Xu L; Yin W; Sun R; Tian Z
    Gastroenterology; 2013 Feb; 144(2):392-401. PubMed ID: 23103614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of NKG2A in immunity and immune-mediated diseases.
    Wang X; Xiong H; Ning Z
    Front Immunol; 2022; 13():960852. PubMed ID: 36032104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.
    Kamiya T; Seow SV; Wong D; Robinson M; Campana D
    J Clin Invest; 2019 May; 129(5):2094-2106. PubMed ID: 30860984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of NKG2A and PD-1 Blockade Improves Radiotherapy Response in Radioresistant Tumors.
    Battaglia NG; Murphy JD; Uccello TP; Hughson A; Gavras NW; Caldon JJ; Gerber SA; Lord EM
    J Immunol; 2022 Aug; 209(3):629-640. PubMed ID: 35840162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.
    Seliger B
    HLA; 2016 Nov; 88(5):213-220. PubMed ID: 27659281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A role of gut microbiota metabolites in HLA-E and NKG2 blockage immunotherapy against tumors: new insights for clinical application.
    Cheng W; Zhu N; Wang J; Yang R
    Front Immunol; 2024; 15():1331518. PubMed ID: 39229258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.